Enterprise Bank & Trust Co Sells 312 Shares of Johnson & Johnson (NYSE:JNJ)

Enterprise Bank & Trust Co lowered its stake in Johnson & Johnson (NYSE:JNJ) by 5.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 5,320 shares of the company’s stock after selling 312 shares during the period. Enterprise Bank & Trust Co’s holdings in Johnson & Johnson were worth $842,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. FCA Corp TX lifted its position in Johnson & Johnson by 1.6% in the third quarter. FCA Corp TX now owns 19,747 shares of the company’s stock valued at $3,076,000 after purchasing an additional 310 shares during the last quarter. Johnson Investment Counsel Inc. raised its holdings in shares of Johnson & Johnson by 1.2% during the third quarter. Johnson Investment Counsel Inc. now owns 229,204 shares of the company’s stock valued at $35,699,000 after acquiring an additional 2,672 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Johnson & Johnson by 6.3% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,398,661 shares of the company’s stock valued at $373,592,000 after acquiring an additional 143,114 shares in the last quarter. Excalibur Management Corp raised its holdings in shares of Johnson & Johnson by 0.3% during the third quarter. Excalibur Management Corp now owns 38,824 shares of the company’s stock valued at $6,047,000 after acquiring an additional 114 shares in the last quarter. Finally, Kesler Norman & Wride LLC raised its holdings in shares of Johnson & Johnson by 1.9% during the third quarter. Kesler Norman & Wride LLC now owns 44,075 shares of the company’s stock valued at $6,865,000 after acquiring an additional 814 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

NYSE JNJ opened at $148.74 on Friday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market cap of $357.97 billion, a P/E ratio of 9.27, a P/E/G ratio of 2.46 and a beta of 0.53. The stock’s fifty day moving average price is $148.05 and its 200-day moving average price is $154.38. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the prior year, the firm posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.33%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analysts Set New Price Targets

A number of equities analysts recently commented on JNJ shares. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Bank of America decreased their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Thursday. Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.